Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News Revance Therapeutics Inc. RVNC

Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are Product and the Service Segment. The Products segment generates maximum revenue which is engaged in the research and development of aesthetic and therapeutic products.


Recent & Breaking News (NDAQ:RVNC)

Revance to Participate in the Guggenheim Nantucket Therapeutics Conference

Business Wire 7 days ago

Revance Announces Two Publications Highlighting the Efficacy and Safety Profile of DAXXIFY(TM) (DaxibotulinumtoxinA-lanm) For Injection in the Aesthetic Surgery Journal

Business Wire 9 days ago

Revance to Present Data from Phase 2 JUNIPER Clinical Trial Evaluating DAXXIFY(TM) (DaxibotulinumtoxinA-lanm) Injection for the Treatment of Upper Limb Spasticity at the International Congress of Parkinson and Movement Disorder Society (MDS)

Business Wire 12 days ago

Revance Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Business Wire 12 days ago

Revance Announces Pricing of $200.0 Million Upsized Public Offering of Common Stock

Business Wire September 12, 2022

Revance Announces Proposed Public Offering of Common Stock

Business Wire September 12, 2022

Revance Announces FDA Approval of DAXXIFY(TM) (DaxibotulinumtoxinA-lanm) for Injection, the First and Only Peptide-Formulated Neuromodulator With Long-Lasting Results

Business Wire September 8, 2022

Revance Reports Second Quarter 2022 Financial Results, Provides Corporate Update

Business Wire August 9, 2022

Revance to Release Second Quarter 2022 Financial Results on Tuesday, August 9, 2022

Business Wire August 2, 2022

Revance To Present Clinical Data on DaxibotulinumtoxinA for Injection at the 2022 TOXINS International Conference

Business Wire July 27, 2022

Revance to Participate in the William Blair 42nd Annual Growth Stock Conference

Business Wire May 23, 2022

Revance Reports First Quarter 2022 Financial Results, Provides Corporate Update

Business Wire May 10, 2022

Revance to Release First Quarter Financial Results on Tuesday, May 10, 2022

Business Wire May 3, 2022

Revance Receives FDA Acceptance of BLA Resubmission for DaxibotulinumtoxinA for Injection for Glabellar Lines

Business Wire April 21, 2022

Revance to Present New Clinical Data on DaxibotulinumtoxinA for Injection from the ASPEN Phase 3 Program at the 2022 American Academy of Neurology Annual Meeting

Business Wire March 28, 2022

Revance Closes on $300 Million Note Purchase Agreement with Athyrium Capital Management

Business Wire March 21, 2022

Revance Resubmits Biologics License Application for DaxibotulinumtoxinA for Injection for Glabellar Lines to the FDA

Business Wire March 8, 2022

Revance to Participate in the Cowen 42nd Annual Health Care Conference

Business Wire March 2, 2022

Revance Reports Fourth Quarter and Full Year 2021 Financial Results, Provides Corporate Update

Business Wire February 28, 2022

Revance to Release Fourth Quarter and Full Year 2021 Financial Results on Monday, February 28, 2022

Business Wire February 22, 2022